DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/g83sfn/entyvio_crohns) has announced the addition of the "Entyvio (Crohn's Disease) - Forecast and Market Analysis to 2022" report to their offering.
The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.
Takeda has developed vedolizumab (MLN0002, formerly known as MLN02 and LDP-02) for the treatment of CD and UC, which is currently undergoing regulatory review in the US and EU. On December 10, 2013, Takeda announced that the FDA's Gastrointestinal Drugs Advisory Committee had unanimously voted to recommend Entyvio for approval as a treatment for adults with moderately to severely active CD and UC.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
8 Entyvio (vedolizumab)
For more information visit http://www.researchandmarkets.com/research/g83sfn/entyvio_crohns